Barriers to participation in actual HIV vaccine trials

Current HIV Research

Volumn 11, Issue 3, 2013, Pages 238-245

  Dhalla, Shayesta ^a   Poole, Gary ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Actual trials; Barriers; HIV; Vaccine

Indexed keywords

ADENOVIRUS VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MIFAMURTIDE; SF2; UNCLASSIFIED DRUG;

DRUG ABUSE; DRUG SAFETY; HETEROSEXUAL FEMALE; HUMAN; MEN WHO HAVE SEX WITH MEN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SOCIAL DISCRIMINATION;

AIDS VACCINES; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; PATIENT PARTICIPATION; SOCIAL DISCRIMINATION;

EID: 84880118667     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X11311030009     Document Type: Review

References (27)

1. Lucero MC, Diaz-Brito V, Murillo BT, et al. Reasons for Not Participating in a Phase 1 Preventive HIV Vaccine Study in a Resource-Rich Country. AIDS Patient Care STDS 2012; 26(7): 379-82.
2. Rida W, Fast P, Hoff R, Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16(3): 195-203.
3. Dhalla S, Poole G. Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. Vaccine 2011; 29(35): 5850-9.
4. OECD Members and Partners. Available at: http://www.oecd.org/about/membersandpartners/
5. Poole G. Using psychological principles to narrow the intentionbehavior gap and increase participation in HIV vaccine trials. Curr HIV Res 2012; 10(6): 552-6.
6. Newman PA, Daley A, Halpenny R, Loutfy M. Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 2008; 26(8): 1091-7.
7. Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection. Vaccine 2011; 29(36): 6130-5.
8. Harro CD, Judson FN, Gorse GJ, et al. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2004; 37(3): 1385-92.
9. Fuchs J, Durham M, McLellan-Lemal E, et al. Negative social impacts among volunteers in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2007; 46(3): 362-8.
10. Pitisuttithum P, Choopanya K, Bussaratid V, et al. Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. J Med Assoc Thai 2007; 90(11): 2442-8.
11. Fishbein M, Ajzen I. Belief, attitude, intention, and behavior: An introduction to theory and research. Reading, MA: Addison-Wesley; 1975.
12. Thapinta D, Jenkins RA, Celentano DD, et al. Evaluation of behavioral and social issues among Thai HIV vaccine trial volunteers. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20(3): 308-14.
13. Jenkins RA, Thapinta D, Morgan PA, et al. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr 2005; 40(5): 592-9.
14. Jenkins RA, Temoshok LR, Virochsiri K. Incentives and disincentives to participate in prophylactic HIV vaccine research. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9(1): 36-42.
15. Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr 2004; 36(1): 604-12.
16. Tarimo EA, Thorson A, Kohi TW, Bakari M, Mhalu F, Kulane A. Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania. PLoS One 2011; 6(2): e14619.
17. Tarimo EA, Thorson A, Kohi TW, et al. A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in Tanzania. BMC Infect Dis 2011; 11: 283.
18. Sheon AR, Wagner L, McElrath MJ, et al. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19(5): 519-26.
19. Gray K, Legg K, Sharp A, et al. Participation in two phase II prophylactic HIV vaccine trials in the UK. Vaccine 2008; 26(23): 2919-24.
20. Jenkins RA, Chinaworapong S, Morgan PA, et al. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(2): 171-7.
21. Thapinta D, Jenkins RA, Morgan PA, et al. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr 2002; 30(5): 503-13.
22. Nyblade L, Singh S, Ashburn K, Brady L, Olenja J. "Once I begin to participate, people will run away from me": understanding stigma as a barrier to HIV vaccine research participation in Kenya. Vaccine 2011; 29(48): 8924-8.
23. Allen M, Israel H, Rybczyk K, et al. Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses 2001; 17(8): 667-74.
24. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16(4): 266-71.
25. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher-and lower-risk volunteers. J Infect Dis 2001; 183(9): 1343-52.
26. Keefer MC, Gilmour J, Hayes P, et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One 2012; 7(8): e41936.
27. Cleghorn F, Pape JW, Schechter M, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr 2007; 46(2): 222-30.